FIELD: pharmaceutical industry.
SUBSTANCE: group of inventions relates to a new gonadotropin-releasing hormone (GnRH) derivative conjugated with palmitic acid and a pharmaceutical composition containing it. The prolonged release palmitic acid-conjugated GnRH derivative is selected from: i) a sodium salt of a GnRH derivative containing the amino acid sequence of SEQ ID NO: 4, ii) an acetate salt of a GnRH derivative containing the amino acid sequence of SEQ ID NO: 5, and iii) an acetate salt of a GnRH derivative containing the amino acid sequence of SEQ ID NO: 6, in which the carboxyl group of palmitic acid is conjugated through a peptide bond to the amino terminus of GnRH. GnRH derivatives exhibit excellent volume of distribution, delayed time to peak concentration after drug administration, enable GnRH to maintain appropriate concentrations for a long period of time in vivo, and have excellent cytotoxic effects.
EFFECT: pharmaceutical composition based on a GnRH derivative is useful for the prevention and treatment of various sex hormone-dependent diseases.
5 cl, 6 dwg, 7tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GnRH DERIVATIVES OF PROLONGED ACTION, CONJUGATED WITH FATTY ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2019 |
|
RU2785717C2 |
| PEGILATED BIOLOGICALLY ACTIVE PEPTIDES AND THEIR APPLICATION | 2017 |
|
RU2748576C2 |
| DIRECTED REGENERATION OF BROKEN BONE BY MEANS OF STIMULATION OF PARATHYROID HORMONE RECEPTOR | 2017 |
|
RU2785401C2 |
| IGG4 Fc FRAGMENT CONTAINING A MODIFIED HINGE REGION | 2014 |
|
RU2800558C1 |
| LONG-ACTING DOUBLE AGONIST OF GLUCAGON-LIKE PEPTIDE-1 AND GLUCAGON RECEPTORS | 2021 |
|
RU2799327C1 |
| INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY TO INSULIN RECEPTOR AND ITS USE | 2018 |
|
RU2779462C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| COMPOSITION FOR TREATING CANCER, COMBINING ANTI-CD26 ANTIBODY AND OTHER ANTI-CANCER AGENT | 2016 |
|
RU2742953C2 |
| MIXTURES AND COMPOSITIONS CONTAINING ALKYLAMMONIUM EDTA SALT | 2017 |
|
RU2775780C2 |
